Clinically Integrated Networks: A Growing Disrupter in American Healthcare

Publish date: 19 Jun, 2019

Download Now

Get the infographic Today!

The Growing Prevalence of Clinically Integrated Networks
View Now

This live session took place on June 13th, 2019

Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Of the 200 state-level IDNs profiled, nearly two-thirds had CINs.

CINs are becoming the primary point of engagement for IDNs and are becoming more crucial to population health management and value-based contracts. To this end, CINs are the foundation for value-based narrow provider networks.

There are many types of IDNs, from major powerhouses within local markets to Academic medical centers, payer/provider networks and other unique arrangements.

Specifically, this webinar covered:

  • What CINs are
  • What makes CINs different from other physician organizations
  • Their role in the overall IDN ecosystem
  • Types of IDNs with specific case studies
  • Implications and strategies for pharma

Presenters:

  • Mark Cherry, Principal Analyst with Market Access
  • Valerie E. Pillo, Senior Analyst with Market Access





Healthbase


The rapid growth and consolidation of IDNs are having a profound impact the delivery of care at both the national and regional levels. This includes greater control on HCP decisions, rising competition with traditional insurers and pharmacies as well as a greater emphasis on value based care.
Can you identify key stakeholder alignments at the local level?

Healthbase has been built to provide multi-disciplinary market access teams with the data and insight they need to understand alignments between systems – down to the individual provider level – and ascertain the market control of IDNs across US regions and patient populations.

Learn more or schedule a demo today.

Learn More

Will Netflix-Style Payment Models be the New Norm For High Cost Drugs?

NEXT ARTICLE